Monopar Therapeutics（MNPR）株式概要モノパー・セラピューティクス社は臨床段階にあるバイオ医薬品会社で、米国でがん治療薬の開発に従事している。 詳細MNPR ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より94.4%で取引されている 収益は年間59.84%増加すると予測されています アナリストらは、株価が78.4%上昇するだろうとほぼ一致している。 リスク分析収益が 100 万ドル未満 ( $0 )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るMNPR Community Fair Values Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$63.12該当なし内在価値ディスカウントEst. Revenue$PastFuture-17m102016201920222025202620282031Revenue US$10.4Earnings US$1.9AdvancedSet Fair ValueView all narrativesMonopar Therapeutics Inc. 競合他社vTv TherapeuticsSymbol: NasdaqCM:VTVTMarket cap: US$426.9mOvid TherapeuticsSymbol: NasdaqCM:OVIDMarket cap: US$427.4mPrelude TherapeuticsSymbol: NasdaqGS:PRLDMarket cap: US$429.5mZura BioSymbol: NasdaqCM:ZURAMarket cap: US$413.7m価格と性能株価の高値、安値、推移の概要Monopar Therapeutics過去の株価現在の株価US$63.1252週高値US$105.0052週安値US$28.40ベータ1.51ヶ月の変化18.65%3ヶ月変化13.12%1年変化78.05%3年間の変化1,276.36%5年間の変化121.09%IPOからの変化-52.36%最新ニュースお知らせ • May 21Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMonopar Therapeutics Inc. announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.” The publication reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease, driven by increased fecal copper excretion. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. The open-label, single-arm Phase 2 trial evaluated daily dosing of ALXN1840 in nine patients with Wilson disease across two centers in the United Kingdom and New Zealand. Patients were admitted to a clinical research unit and initiated on a copper-controlled diet, with all copper intake and output collected during a pre-treatment baseline period and after initiation of daily ALXN1840 over multiple weeks. The publication builds on a recently published peer-reviewed Journal of Hepatology Letter to the Editor, which highlighted the importance of comparing outcomes to a pre-treatment baseline to accurately assess the effect of a potential Wilson disease treatment on copper balance. Statistically significant reduction in daily copper balance from baseline, due to increased fecal copper excretion. Cumulative mean decrease from baseline in copper balance of -6.08 mg over 21 days (95% CI: -10.18 mg to -1.98 mg). Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during the 15 mg/day treatment period and -0.29 mg (p=0.023) through the overall study period. Approximately 50% increase in the daily fecal copper output-to-intake ratio compared to baseline (p=0.041). Immediate increases in plasma total copper and directly measured non-ceruloplasmin-bound copper (dNCC), consistent with copper mobilization and formation of stable albumin tripartite complexes (ATCs) consisting of copper, ALXN1840, and albumin. ALXN1840 was generally well tolerated; no serious adverse events were reported. The observed improvements in copper balance and copper mobilization occurred in a Wilson disease patient population with a mean prior current standard of care treatment duration of 16 years, suggesting that despite years of treatment with currently available therapies, patients present with a considerable amount of residual copper in the body that ALXN1840 is able to mobilize and eliminate. This finding is consistent with data from the completed 48-week Phase 3 trial, in which ALXN1840 demonstrated superior copper mobilization compared to standard of care even in patients with a mean prior standard of care treatment duration of 11 years. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.分析記事 • May 07Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • May 04Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026. Location: at 1000 skokie blvd., wilmette, il 60091, United Statesお知らせ • Apr 20Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic SymptomsMonopar Therapeutics Inc. announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department of Neurology, University of Louisville School of Medicine, will present results showing that ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable neurologic benefit observed over multiple years of treatment. In the randomized FoCus trial, analysis of patients with neurologic symptoms at baseline (TMC: n=77; SoC: n=35) demonstrated that treatment with ALXN1840 resulted in both higher rates of improvement and lower rates of worsening, addressing a critical unmet need in the neurologic management of Wilson disease. Clinically meaningful neurologic worsening at Week 48 was observed in 25% of patients treated with standard of care vs 9% of ALXN1840-treated patients (p=0.038). Clinically meaningful neurologic improvement at Week 48 was observed in 45% of ALXN1840-treated patients vs 32% on standard of care. CGI-S improvement from baseline to Week 48 was greater with ALXN1840 vs standard of care (61% vs 17%; p=0.008). CGI-I improvement at Week 48 was greater with ALXN1840 vs standard of care (47% vs 19%; p=0.003). Durable neurologic benefit in the ALXN1840-treated group continued to increase during long-term follow-up on treatment and was sustained over approximately 3 years. Neurologic benefit was consistent across both treatment-naïve and treatment-experienced patients with neurologic symptoms at baseline, supporting ALXN1840’s potential as a novel treatment option for Wilson disease. ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious adverse events (SAEs) limited to 4.9% of patients — including neurologic SAEs in < 1% — and no treatment-related deaths. These findings support the continued advancement of ALXN1840 toward the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026. Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body's ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.Recent Insider Transactions Derivative • Apr 07Co-Founder exercised options and sold US$108k worth of stockOn the 31st of March, Chandler Robinson exercised options to acquire 2k shares at no cost and sold these for an average price of US$54.79 per share. This trade did not impact their existing holding. For the year to December 2019, Chandler's total compensation was 53% salary and 47% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Chandler's direct individual holding has increased from 73.47k shares to 153.29k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Mar 03Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective March 2, 2026. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. Susan Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.最新情報をもっと見るRecent updatesお知らせ • May 21Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMonopar Therapeutics Inc. announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.” The publication reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease, driven by increased fecal copper excretion. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. The open-label, single-arm Phase 2 trial evaluated daily dosing of ALXN1840 in nine patients with Wilson disease across two centers in the United Kingdom and New Zealand. Patients were admitted to a clinical research unit and initiated on a copper-controlled diet, with all copper intake and output collected during a pre-treatment baseline period and after initiation of daily ALXN1840 over multiple weeks. The publication builds on a recently published peer-reviewed Journal of Hepatology Letter to the Editor, which highlighted the importance of comparing outcomes to a pre-treatment baseline to accurately assess the effect of a potential Wilson disease treatment on copper balance. Statistically significant reduction in daily copper balance from baseline, due to increased fecal copper excretion. Cumulative mean decrease from baseline in copper balance of -6.08 mg over 21 days (95% CI: -10.18 mg to -1.98 mg). Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during the 15 mg/day treatment period and -0.29 mg (p=0.023) through the overall study period. Approximately 50% increase in the daily fecal copper output-to-intake ratio compared to baseline (p=0.041). Immediate increases in plasma total copper and directly measured non-ceruloplasmin-bound copper (dNCC), consistent with copper mobilization and formation of stable albumin tripartite complexes (ATCs) consisting of copper, ALXN1840, and albumin. ALXN1840 was generally well tolerated; no serious adverse events were reported. The observed improvements in copper balance and copper mobilization occurred in a Wilson disease patient population with a mean prior current standard of care treatment duration of 16 years, suggesting that despite years of treatment with currently available therapies, patients present with a considerable amount of residual copper in the body that ALXN1840 is able to mobilize and eliminate. This finding is consistent with data from the completed 48-week Phase 3 trial, in which ALXN1840 demonstrated superior copper mobilization compared to standard of care even in patients with a mean prior standard of care treatment duration of 11 years. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.分析記事 • May 07Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • May 04Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026. Location: at 1000 skokie blvd., wilmette, il 60091, United Statesお知らせ • Apr 20Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic SymptomsMonopar Therapeutics Inc. announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department of Neurology, University of Louisville School of Medicine, will present results showing that ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable neurologic benefit observed over multiple years of treatment. In the randomized FoCus trial, analysis of patients with neurologic symptoms at baseline (TMC: n=77; SoC: n=35) demonstrated that treatment with ALXN1840 resulted in both higher rates of improvement and lower rates of worsening, addressing a critical unmet need in the neurologic management of Wilson disease. Clinically meaningful neurologic worsening at Week 48 was observed in 25% of patients treated with standard of care vs 9% of ALXN1840-treated patients (p=0.038). Clinically meaningful neurologic improvement at Week 48 was observed in 45% of ALXN1840-treated patients vs 32% on standard of care. CGI-S improvement from baseline to Week 48 was greater with ALXN1840 vs standard of care (61% vs 17%; p=0.008). CGI-I improvement at Week 48 was greater with ALXN1840 vs standard of care (47% vs 19%; p=0.003). Durable neurologic benefit in the ALXN1840-treated group continued to increase during long-term follow-up on treatment and was sustained over approximately 3 years. Neurologic benefit was consistent across both treatment-naïve and treatment-experienced patients with neurologic symptoms at baseline, supporting ALXN1840’s potential as a novel treatment option for Wilson disease. ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious adverse events (SAEs) limited to 4.9% of patients — including neurologic SAEs in < 1% — and no treatment-related deaths. These findings support the continued advancement of ALXN1840 toward the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026. Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body's ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.Recent Insider Transactions Derivative • Apr 07Co-Founder exercised options and sold US$108k worth of stockOn the 31st of March, Chandler Robinson exercised options to acquire 2k shares at no cost and sold these for an average price of US$54.79 per share. This trade did not impact their existing holding. For the year to December 2019, Chandler's total compensation was 53% salary and 47% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Chandler's direct individual holding has increased from 73.47k shares to 153.29k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Mar 03Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective March 2, 2026. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. Susan Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.Recent Insider Transactions Derivative • Jan 07Chief Operating Officer exercised options and sold US$123k worth of stockOn the 31st of December, Andrew Cittadine exercised options to acquire 2k shares at no cost and sold these for an average price of US$65.30 per share. This trade did not impact their existing holding. Since March 2025, Andrew's direct individual holding has increased from 41.99k shares to 50.73k. Company insiders have collectively sold US$2.9m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Dec 30Key Executive recently bought US$105k worth of stockOn the 26th of December, Quan Vu bought around 2k shares on-market at roughly US$69.95 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Quan's only on-market trade for the last 12 months.Recent Insider Transactions • Dec 21Independent Director recently sold US$344k worth of stockOn the 18th of December, Arthur Klausner sold around 5k shares on-market at roughly US$67.15 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.分析記事 • Nov 22Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Current...お知らせ • Nov 10Monopar Therapeutics Inc. Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025Monopar Therapeutics Inc. announced that it is presenting new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025. In an oral presentation titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Professor of Hepatology and Consultant Hepatologist at the Institute of Liver Studies at King's College Hospital in London, will be sharing results showing that treatment with ALXN1840 (tiomolybdate choline) led to a rapid and sustained improvement in daily copper balance in patients with Wilson disease, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 in the study (n=8) was significantly lower - indicating improvement - compared with their pre-treatment baseline. Copper balance improved both during the initial 15 mg once-daily dosing period (days 1-28) and over the entire treatment duration (days 1-39), which included patients receiving either 15 mg every other day or 30 mg once daily. Additional new nonclinical and clinical data supporting these findings from the ALXN 1840-WD-204 study will also be presented.Seeking Alpha • Oct 10Monopar Therapeutics: A Healthy Dose Of Skepticism WarrantedSummary Monopar Therapeutics has surged nearly 2,000% in a year, driven by the acquisition of ALXN-1840 and positive MNPR-101-Zr data. ALXN-1840, acquired from AstraZeneca, targets Wilson disease with an NDA filing anticipated in early 2026, but approval remains uncertain. MNPR's radiopharmaceutical pipeline is in early stages, with limited data and no clear timeline for further results. An analysis around this remarkable biotech comeback story follows in the paragraphs below. Read the full article on Seeking AlphaRecent Insider Transactions Derivative • Oct 03Chief Operating Officer exercised options and sold US$155k worth of stockOn the 30th of September, Andrew Cittadine exercised options to acquire 2k shares at no cost and sold these for an average price of US$81.67 per share. This trade did not impact their existing holding. Since December 2024, Andrew's direct individual holding has increased from 40.94k shares to 48.29k. Company insiders have collectively sold US$2.3m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Sep 24Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $134.998998 million.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $134.998998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,034,433 Price\Range: $67.67 Discount Per Security: $4.0602 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 960,542 Price\Range: $67.669 Discount Per Security: $4.0602 Transaction Features: Registered Direct Offeringお知らせ • Sep 15Monopar Therapeutics Inc. to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual MeetingMonopar Therapeutics Inc. announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The analysis pooled efficacy outcomes from three independent clinical trials (n=255), while safety data included a fourth independent clinical trial (n=266). Median treatment duration with ALXN1840 was approximately 2.6 years for both the efficacy and safety analyses. The new data presented at ANA highlight the long-term neurological benefit of ALXN1840, and follow the recent presentation of long-term hepatic and systemic efficacy and safety data at the European Association for the Study of the Liver (EASL) International Liver Congress 2025. Together, these findings underscore the potential of ALXN1840 for both the neurological and hepatic manifestations of Wilson disease. Key findings to be presented at ANA include: Sustained Neurological Improvement: Statistically significant neurologic improvement from baseline on the Unified Wilson Disease Rating Scale ("UWDRS") Part II (patient-reported symptoms) and Part III (clinician-reported symptoms) was sustained over 6 years. Crossover Benefit: Patients who crossed over from standard of care ("SoC") to ALXN1840 showed additional neurological improvement, including a majority of patients who had worsened on SoC demonstrating a reversal on ALXN1840. Psychiatric Outcomes: Statistically significant psychiatric improvement from baseline was sustained over multiple years, as measured by the Brief Psychiatric Rating Scale ("BPRS"). Consistency Across Trials: Neurological benefit was observed consistently across multiple independent studies. Favorable Safety Profile: Across more than 645 patient-years on ALXN1840, less than 1% of patients experienced a drug-related neurological serious adverse event (“SAE”).New Risk • Sep 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$17m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).Price Target Changed • Aug 27Price target increased by 8.0% to US$67.17Up from US$62.18, the current price target is an average from 6 analysts. New target price is 93% above last closing price of US$34.81. Stock is up 1,440% over the past year. The company is forecast to post a net loss per share of US$1.77 next year compared to a net loss per share of US$4.11 last year.Price Target Changed • Jul 07Price target increased by 7.6% to US$63.18Up from US$58.69, the current price target is an average from 6 analysts. New target price is 70% above last closing price of US$37.20. Stock is up 908% over the past year. The company is forecast to post a net loss per share of US$1.98 next year compared to a net loss per share of US$4.11 last year.お知らせ • Jun 11Monopar Therapeutics Inc. and Excel Diagnostics and Nuclear Oncology Center Announce Expanded Access Program for Mnpr-101-Zr and Mnpr-101-Lu in Advanced CancersMonopar Therapeutics Inc. in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC) announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration (FDA). The MNPR-101 EAP is now open for enrollment to patients with advanced solid tumors at EDNOC in Houston, Texas. EDNOC is among the first private outpatient facilities in the U.S. to be designated as a Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”). Patients will be treated under the supervision of renowned investigator Ebrahim S. Delpassand, MD, founder and medical director of EDNOC.お知らせ • May 07Monopar Therapeutics Inc. Presents ALXN1840 Late-Breaker Data At EASL 2025Monopar Therapeutics Inc. is presenting data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, one of the most prominent global conferences in liver disease. The poster supports the potential use of ALXN1840 as a therapeutic option for Wilson disease, a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in tissues and organs such as the liver and brain. Efficacy data were pooled and analyzed from three clinical trials: Phase 2 WTX101-201, Phase 2 ALXN1840-WD-205, and Phase 3 WTX101-301 (n=255). For safety analysis, data from the Phase 2 ALXN18 40-WD-204 trial were also included (n=266). The median treatment duration with ALXN1840 was 961 days (2.63 years) and 943.5 days (2.58 years) for the efficacy and safety datasets, respectively. The data presented highlight the following: Sustained improvements from baseline in the Unified Wilson Disease Rating Scale ("UWDRS") Part II (patient-reported symptoms) and Part III (clinician-assessed symptoms); Increased copper mobilization as evidenced by a sustained increase in dNCC (directly measured non-ceruloplasmin-bound copper); Improvements on the Clinical Global Impression - Improvement ("CGI-I") scale for ALXN1840 compared to standard of care; Improvement in the New Wilson Index (based on bilirubin, AST, INR, leukocytes, and albumin) for patients treated with ALXN1840; Higher patient-reported convenience and effectiveness of ALXN1840 compared To standard of care, including those who transitioned from standard of care to ALXN1840 in the extension portion of the Phase 3 clinical trial; and Fewer than 5% of patients experienced a drug-related serious adverse event ("SAE"), with no cases of a drug-related renal or urinary system SAE.お知らせ • May 01Monopar Therapeutics Inc., Annual General Meeting, Jun 17, 2025Monopar Therapeutics Inc., Annual General Meeting, Jun 17, 2025. Location: 1000 skokie blvd, wilmette, il 60091, United StatesBreakeven Date Change • Apr 02No longer forecast to breakevenThe 4 analysts covering Monopar Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.58m in 2027. New consensus forecast suggests the company will make a loss of US$6.91m in 2027.お知らせ • Apr 01Monopar Therapeutics Inc. Announces Recent Program DevelopmentsMonopar Therapeutics Inc. announced Recent Program Developments. ALXN1840 – Plan to Submit NDA with FDA for Wilson Disease in Early 2026. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in tissues and organs such as the liver and brain. ALXN1840 is a potent binder and mobilizer of copper, as demonstrated in a Phase 3 clinical trial that met its primary endpoint. In October 2024, Monopar announced the execution of a worldwide exclusive license to ALXN1840 with Alexion, AstraZeneca Rare Disease (“AZ”). As part of this transaction, AZ received a total cash payment of $4.0 million, was issued 9.9% ownership of Monopar’s outstanding common stock, and is entitled to receive regulatory approval and sales milestones along with a tiered royalty based on net sales. MNPR-101 – Currently Enrolling Phase 1 Imaging and Therapeutic Oncology Trials Imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) and therapeutic agent MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) target the urokinase plasminogen activator receptor (“uPAR”), which is expressed in numerous aggressive cancers such as triple-negative breast, colorectal, and pancreatic cancers. · Initiated Phase 1a clinical trial for novel therapeutic radiopharmaceutical MNPR-101-Lu in patients with advanced cancers · Dosed first patient with MNPR-101-Lu in December 2024 · Presented encouraging human clinical imaging and dosimetry data of MNPR-101-Zr at the European Association of Nuclear Medicine (“EANM”) 2024 Annual Congress · uPAR expression, as detected by MNPR-101-Zr, has been seen to date in breast, colorectal, pancreatic, adrenocortical carcinoma, and ovarian cancer patients · Filed a patent application covering new therapeutic radiopharmaceuticals based on a novel family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101.New Risk • Mar 31New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$6.5m Forecast net loss in 3 years: US$71k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$71k net loss in 3 years).Price Target Changed • Mar 19Price target increased by 15% to US$53.25Up from US$46.50, the current price target is an average from 4 analysts. New target price is 36% above last closing price of US$39.10. Stock is up 919% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$3.04 last year.Breakeven Date Change • Mar 06Forecast to breakeven in 2027The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.44m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.お知らせ • Mar 05+ 1 more updateMonopar Therapeutics Inc. Announces Executive ChangesOn February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated. As of such date, Mr. Radhakrishan will no longer serve as the Company’s principal financial officer, or principal accounting officer. On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s principal accounting officer and principal financial officer effective March 3, 2025. Mr. Vu brings over 20 years of corporate and financial strategy, investment banking and public company experience. From October 2024 through February 2025, Mr. Vu served as a Venture Partner of ZhongMei Capital. In 2023 he served as Chief Financial Officer and Chief Business Officer of Ocugen Inc. and prior to that, he served as Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. from November 2021 to January 2023. Before joining 180 Life Sciences and since 2019, Mr. Vu has provided services as a consultant/independent contractor through his own consulting firm, Melius BioPharma Consulting. Under Melius, he has served in various capacities for the following companies: 1) LS Associates, a life science services firm and a member company of LifeSci Partners, as an interim C-suite consultant since July 2020; 2) Baleena Bioscience Inc., a biomedical company focused on healthspan, as CEO from April 2021 through October 2021; and 3) Solganick & Co., a technology investment banking firm, as Managing Director and Co-Head of Healthcare IT, from September 2019 through October 2021 and again from August 2024 through February 2025. From September 2016 to August 2019, Mr. Vu served as Vice President and Head of Strategy and Corporate & Business Development at Opiant Pharmaceuticals Inc. Prior to Opiant, he held leadership roles of increasing responsibility at Impax Laboratories Inc., Elevance Health Inc. (formerly Anthem Inc.) and Amgen Inc. Earlier in his career, he worked in the healthcare corporate finance and M&A departments at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. Mr. Vu obtained his MS in Legal Studies from Cornell University Law School and BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).Seeking Alpha • Mar 04Monopar Therapeutics: Strong Data, But There Are RisksSummary Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results. The market for Wilson Disease treatments is small, with limited pricing power due to existing generic therapies. Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. Key risks include the need for future funding and competition from Pfizer's gene therapy, VTX-801, which is still years from market. Read the full article on Seeking AlphaNew Risk • Jan 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$6.5m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (78% average daily change). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years).Breakeven Date Change • Dec 31Forecast to breakeven in 2027The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$3.75m in 2027. Average annual earnings growth of 47% is required to achieve expected profit on schedule.お知らせ • Dec 21Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 798,655 Price\Range: $23.79 Transaction Features: Registered Direct Offeringお知らせ • Dec 06Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-LuMonopar Therapeutics Inc. announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. The MNPR-101-Lu intravenous infusion was well-tolerated with no serious adverse reactions reported. This patient, dosed under a compassionate use protocol in the US, has metastatic pancreatic cancer, and prior to dosing, the cancer was imaged using MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) with a PET/CT scanner and showed uPAR expression. Monopar is actively enrolling participants in two Phase 1 clinical studies in Australia, evaluating MNPR-101-Zr for imaging and MNPR-101-Lu for treatment of advanced solid tumors.Price Target Changed • Nov 20Price target increased by 51% to US$27.33Up from US$18.07, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$19.01. Stock is up 1,191% over the past year. The company is forecast to post a net loss per share of US$1.77 next year compared to a net loss per share of US$3.04 last year.お知らせ • Oct 31Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million.Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,181,540 Price\Range: $16.25 Discount Per Security: $1.1375New Risk • Oct 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 86% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (77% average daily change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Market cap is less than US$100m (US$85.6m market cap).お知らせ • Oct 29Monopar Therapeutics Inc. has filed a Follow-on Equity Offering.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stockお知らせ • Oct 16Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and LinkersMonopar Therapeutics Inc. announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar's uPAR targeted agents linked with these along with therapeutic radioisotopes; Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar's array of therapeutic radiopharmaceuticals; and that this provisional patent could enable Monopar to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets of interest to Monopar or others in the industry opening the door to potential licensing and development collaborations.お知らせ • Oct 07Monopar Therapeutics Inc. Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced CancersMonopar Therapeutics Inc. announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to zirconium-177) is now active and recruiting patients with advanced cancers. The Phase 1a trial is an open-label dose-escalation study of MNPR-101-Lu in patients with solid tumors. The first clinical trial site activated for the study is the Melbourne Theranostic Innovation Centre (MTIC) in Australia. To help identify those patients most likely to benefit from MNPR-101-Lu, the trial will only be open to those participating in the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial. MNPR-101 is Monopar's proprietary antibody that targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal, ovarian, and bladder. By selectively targeting uPAR, Monopar aims to deliver a radiopharma therapy that kills cancer cells while minimizing damage to healthy tissue. Both clinical (link) and preclinical (link) data to date have demonstrated highly specific and durable tumor uptake of MNPR-101- Zr (MNPR-101 conjUGated to zirconium -89).お知らせ • Aug 28Monopar Regains Compliance with Nasdaq Minimum Bid Price RuleMonopar Therapeutics Inc. announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.お知らせ • Aug 22Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersMonopar Therapeutics Inc. announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101, which is highly selective against the urokinase plasminogen activator receptor (uPAR). The MNPR-101-Lu Phase 1 clinical trial will enroll patients with advanced solid cancers and will be a therapeutic follow-on study to the currently ongoing MNPR-101-Zr imaging and dosimetry clinical trial. The results from preclinical studies of MNPR-101-Lu are promising. In a 90-day efficacy study in a human pancreatic cancer xenograft mouse model as an example, MNPR-101-Lu demonstrated durable antitumor effects after a single injection, achieving complete elimination of tumors that lasted the duration of the study. The MNPR-101-Lu imaging data in a human pancreatic cancer xenograft mouse model presented in March provides additional insight into the strong therapeutic effect observed after a single injection of MNPR-101-Lu. The imaging data demonstrates the high specificity and durable uptake of MNPR-101-Lu in the tumor relative to normal tissue.お知らせ • Aug 14Monopar Therapeutics Inc. Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrMonopar Therapeutics Inc. announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr. MNPR-101-Zr was well-tolerated with no serious adverse reactions reported through the last imaging timepoint and the corresponding initial safety review. Preliminary analysis of MNPR-101-Zr’s pharmacokinetics and biodistribution suggests the low radiation dose to healthy tissue aligns with what was anticipated based on the previously presented MNPR-101-Zr preclinical biodistribution data. Dosimetry analysis showed absorbed organ doses were well below accepted safety limits; for example, the radiation dose to red bone marrow was about 14 mGy, which is around 150 times less than the generally accepted limit of 2-to-3 Gy. No unanticipated or excessive uptake of MNPR-101-Zr was observed in any critical organs through the end of the subject’s imaging period. The patient has metastatic disease from a cancer type not known for high uPAR expression. The study aims to include several patients with cancers known to express high levels of uPAR to gain insight into MNPR-101-Zr’s tumor uptake profile, in addition to patients with cancers of unknown uPAR expression.分析記事 • Aug 13We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.68m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.2m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.68m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Shareholders have been diluted in the past year (33% increase in shares outstanding).New Risk • Jul 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.2m free cash flow). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).New Risk • Jul 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 18% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (US$12.9m market cap).お知らせ • Jul 13Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024. Location: 1000 skokie blvd., wilmette, il 60091, United Statesお知らせ • Jul 09Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-ZrMonopar Therapeutics Inc. announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel radiopharmaceutical imaging agent combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the radioisotope zirconium-89. Monopar’s Phase 1 clinical trial, led by internationally recognized nuclear medicine physician Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers. This is the first human study to evaluate a radiolabeled monoclonal antibody targeting uPAR.お知らせ • May 26Monopar Therapeutics Inc. Announces CFO ChangesMonopar Therapeutics Inc. announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar’s Board of Directors. Monopar has been working over the past 6-plus months on a consulting basis with Karthik Radhakrishnan. Effective July 1, 2024, Mr. Radhakrishnan will be appointed Monopar’s Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer. Mr. Radhakrishnan brings over 20 years of financial strategy, investment and public company experience. Mr. Radhakrishnan has served as President and founder of Titania Partners LLC, a management consulting firm focused on the life science sector during which time he served as Chief Financial Officer of Santalis Pharmaceuticals Inc. and Chief Executive Officer of Asylia Therapeutics Inc. He has also previously served as Chief Financial Officer of Opexa Therapeutics Inc. and before that as Vice President at ING Investment Management in New York. Mr. Radhakrishnan is a Certified Financial Advisor charter holder and holds a B.S. in Chemical Engineering from Indian Institute of Technology, an M.S. in Civil and Environmental Engineering from State University of New York at Buffalo and an M.B.A. from University of Michigan Business School.Price Target Changed • May 12Price target decreased by 38% to US$2.08Down from US$3.36, the current price target is an average from 2 analysts. New target price is 209% above last closing price of US$0.67. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.36 next year compared to a net loss per share of US$0.61 last year.お知らせ • Apr 16Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsMonopar Therapeutics Inc. announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled “Antibody Radioisotope Constructs” that was filed with the United States Patent and Trademark Office (USPTO) outlines the MNPR-101-Zr construct, including variations on the radioisotopes, linkers, and antibody which could enhance the clinical profile of the construct, including properties such as its stability and biodistribution. It also covers the formulations and uses of MNPR-101-Zr, a zirconium-89 imaging radioisotope labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly-selective against the urokinase plasminogen activator receptor (uPAR). Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR. Monopar recently announced the initiation of its Phase 1 dosimetry clinical trial for MNPR-101-Zr in patients with advanced cancers.お知らせ • Apr 10Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsMonopar Therapeutics Inc. announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed on numerous tumor types including pancreatic, breast, colorectal, and bladder. The study is now open for enrollment at the Melbourne Theranostic Innovation Centre (MTIC) in Australia, and is being led by Professor Rodney Hicks, an internationally recognized physician and pioneer in the radiopharma space. MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients. The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer. Preclinical data to date have shown highly specific and durable tumor uptake of MNPR-101-Zr in human cancer xenograft models. Moreover, Monopar recently shared positive preclinical efficacy data showing potent and durable anti-tumor activity of MNPR-101 bound to therapeutic radioisotopes. If the tumor uptake, biodistribution, and safety look encouraging in this Phase 1 clinical trial for MNPR-101-Zr, the Company plans to expand the study or initiate a new study to test the potential efficacy of MNPR-101 bound to a therapeutic radioisotope such as Ac-225 in patients with advanced cancers.Price Target Changed • Apr 01Price target decreased by 52% to US$4.05Down from US$8.50, the current price target is an average from 2 analysts. New target price is 496% above last closing price of US$0.68. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.61 last year.お知らせ • Mar 05Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramMonopar Therapeutics Inc. announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR (urokinase plasminogen activator receptor) targeting agent MNPR-101. The data clearly demonstrate highly preferential uptake in the tumor. This is an extension of the tumor imaging and efficacy data Monopar released on February 22 (link), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models. The new imaging data released provide additional support for the tumor-targeting ability of MNPR-101 and help explain the near complete elimination of tumors observed after a single injection of therapeutic radioisotopes bound to MNPR-101. Two of the most commercially successful radiopharmaceuticals, Pluvicto and Lutathera, use the therapeutic radioisotope Lutetium-177 (Lu-177). Beyond killing cancer cells, this radioisotope has the added advantage that its biodistribution can be visualized via SPECT (single-photon emission computed tomography) imaging. Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model. High specificity and durable uptake of MNPR-101-Lu in the tumor relative to normal tissue is readily apparent, and these results are consistent with the previously released data for Monopar’s diagnostic imaging radiopharmaceutical MNPR-101-Zr. Monopar recently announced it received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients. The data disclosed further support Monopar’s efforts to create a radiodiagnostic and radiotherapeutic pairing to image and treat uPAR-positive cancers.お知らせ • Feb 29Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price RequirementAs previously reported, on August 28, 2023, Monopar Therapeutics Inc. (the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"), and the Company was provided an initial period of 180 calendar days, or until February 26, 2024 (the Compliance Date"), to regain compliance with the Bid Price Requirement. On February 27, 2024, the Company received a letter from Nasdaq notifying that the Company had been granted an additional 180-day extension to August 26, 2024 (Extended Compliance Period") to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time during the Extended Compliance Period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days or up to 20 business days in certain circumstances in NASDAQ's discretion, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company cannot demonstrate compliance during the Extended Compliance Period, the Staff will provide notice that the Company's common stock will be subject to delisting. At that time, the Company may appeal the Staff's determination to a hearings panel. The Company intends to continue to monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, including potentially implementing a reverse stock split (if approved by the Company's shareholders). There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement during the Extended Compliance Period or will otherwise be in compliance with other Nasdaq listing requirements.分析記事 • Feb 27Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Feb 23Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersMonopar Therapeutics Inc. announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers. MNPR-101 Conjugated to Imaging Radioisotope: Maximizing the dose delivered to the tumor relative to normal tissue is of paramount importance in radiopharmaceutical therapy. Monopar’s in-house radiopharmaceutical development team was able to significantly increase tumor uptake of MNPR-101-Zr while minimizing uptake in healthy tissue, as shown in this preclinical positron emission tomography (PET) sequential imaging time-series. The high specificity and durable tumor uptake are evident in the After Optimization panel below. MNPR-101 Conjugated to Therapeutic Radioisotopes: Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes. Figure 2 below shows preclinical efficacy data in a triple negative breast cancer as well as a pancreatic cancer human tumor xenograft mouse model utilizing two different therapeutic radioisotopes conjugated to MNPR-101; one of these radioisotopes has already been disclosed as being actinium-225 (Ac-225). The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients.お知らせ • Feb 20Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersMonopar Therapeutics Inc. announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety. MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against the urokinase plasminogen activator receptor (uPAR). PET imaging studies in preclinical xenograft models of triple-negative breast, colorectal, and pancreatic cancers displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors. The imaging results, along with corresponding in vivo efficacy studies with actinium-225 (Ac-225, a powerful alpha-emitting therapeutic radioisotope) bound to MNPR-101 in preclinical xenograft tumor models, support the development MNPR-101 as a targeted radiopharmaceutical for multiple advanced cancer indications. If the tumor uptake, biodistribution, and safety look encouraging in this Phase 1 clinical trial, which is anticipated to enroll around 12 patients and to initiate in the near future, the plan is to evaluate the efficacy in humans of a therapeutically radio-labeled version of MNPR-101 bound to an isotope such as Ac-225.New Risk • Dec 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$5.42m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Shareholders have been diluted in the past year (16% increase in shares outstanding).New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$7.22m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding).お知らせ • Nov 02Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingMonopar Therapeutics Inc. will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later on November 1, 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, which is bringing together the world's leading sarcoma specialists. Clinical Trial Results To-Date: The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts. The trial is currently ongoing and is in the fifth dose level cohort (650 mg/m2). So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment. All patients in the fourth and fifth cohorts achieved stable disease, including the three most recently treated patients, each of whom also experienced an ~20% tumor size reduction at last study scan. One of these patients had unresectable cancer at study entry, but after the tumor size reduction, the patient became eligible for resection and underwent successful surgical removal of their cancer with clear margins. No dose-limiting toxicity, as defined in the protocol, has been observed to-date. A medically complex patient in the 650 mg/m2 dose cohort has an ongoing left ventricular ejection fraction (LVEF) decrease that is being monitored. This patient has a BMI of 42.5, one kidney, hypertension, a long standing heart murmur, and a maternal history of heart failure. No toxicities have occurred requiring expansion of a dose cohort, and the maximum tolerated dose (MTD) has not been reached.お知らせ • Sep 01Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price RequirementOn August 28, 2023, Monopar Therapeutics Inc. received a letter (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Bid Price Requirement’). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol ‘MNPR.’ In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until February 26, 2024 (the ‘Compliance Date’), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Requirement by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, as of the Compliance Date and would need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to the Nasdaq Hearings Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination, such an appeal would be successful. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements.New Risk • Aug 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.09m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.90m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).お知らせ • Aug 09Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical TrialMonopar Therapeutics Inc. provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg/m2 dose level have experienced tumor size reductions – of 18% and 20% respectively – after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction. The Phase 1b clinical trial data is continuing to support Monopar’s dose-response hypothesis with camsirubicin. The best response seen prior to the current 650 mg/m2 dose level was at the immediately prior dose level (520 mg/m2), which was a 21% reduction in tumor size in a patient after receiving six cycles of camsirubicin treatment. This patient’s cancer was unresectable at study entry, but after the tumor size reduction, became eligible and the patient underwent successful surgical removal of their cancer with clear margins. Furthermore, all three patients at the 520 mg/m2 dose level achieved stable disease and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug. Additionally, no drugrelated cardiotoxicity has been observed in the trial to date as evaluated by the industry standard left ventricular ejection fraction (LVEF), and no toxicities have been experienced by any patient that have required expanding the size of a dose cohort. Further, 71% of camsirubicin patients have experienced no hair loss, and only approximately 14% have experienced >50% hair loss, with the remainder having low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 14% of camsirubicin patients in the Phase 1b trial have experienced mild-to-severe oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin-treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis. ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes. The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.67m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$9.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).お知らせ • Jun 02Monopar Therapeutics Inc. Announces Encouraging Camsirubicin Phase 1b Trial UpdateMonopar Therapeutics Inc. announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Background on ASTS and Camsirubicin ASTS is a diverse type of cancer that typically develops in the connective tissue of the body and which has metastasized (spread) or is not amenable to surgery. Currently, doxorubicin is the first-line standard of care treatment for most types of ASTS. Doxorubicin is one of the most widely used cancer drugs worldwide with FDA approval in ASTS and 13 additional cancer indications. Unfortunately, although higher doses of doxorubicin are known to be more effective at treating cancer, the risk of irreversible heart damage increases with the cumulative dose and limits the lifetime amount that a patient can receive. The hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes. Updates from Currently Enrolling Phase 1b Clinical Trial: One patieient at the 520 mg/m2 dose level, unresectable at study entry, was deemed eligible for tumor resection after several cycles of camsirubic in treatment and a corresponding 21% reduction in tumor dimensions. This patient recently underwent surgical resection of the cancer. This is supportive of doseSHY-response hypothesis with camsirubicin. Two patients are currently enrolled in the fifth dose-SHYlevel cohort (650 mg/m2), which is nearly 2.5x the dose evaluated in any prior camsirubicin clinical trial (265mg/m2). No drugSHY-related cardiotoxicity has been observed in this trial to-date as evaluated by the industry standard left ventricular ejection fraction (LVEF). As previously reported, this trial continues to show less frequent and less severe hair loss and oral mucositis with camsirubic in patients with ASTS, with GEIS as the study sponsor with support from Monopar.Price Target Changed • Mar 29Price target decreased by 49% to US$9.80Down from US$19.29, the current price target is an average from 5 analysts. New target price is 576% above last closing price of US$1.45. Stock is down 44% over the past year. The company is forecast to post a net loss per share of US$0.69 next year compared to a net loss per share of US$0.83 last year.分析記事 • Mar 02Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...お知らせ • Feb 15Monopar Therapeutics Inc. Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to DoxorubicinMonopar Therapeutics Inc. announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS): Monopar has opened enrollment for the fifth dose level cohort, at an increased dose of 650 mg/m2, which is nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial. To date, no drug-related cardiotoxicity has been observed with camsirubicin treatment as evaluated by the industry standard left-ventricular ejection fraction (LVEF). This compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin treatment, the current first-line treatment for ASTS. Only 17% of camsirubicin patients in the trial have experienced low grade hair loss; another 8% have experienced >50% hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 8% of camsirubicin patients in the trial have experienced low grade mild oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis. In addition to the initial Sarcoma Oncology Research Center clinical trial site in Santa Monica, CA, Monopar recently welcomed a second clinical trial site with Dr. Lee Cranmer and the Sarcoma Clinic at the Fred Hutchinson Cancer Center/University of Washington in Seattle, WA.お知らせ • Jan 28Monopar Therapeutics Inc. Announces Projected Timeline of Upcoming Quarter 1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RITMonopar Therapeutics Inc. announced it is planning to report over the next two months: the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, clinical data from its camsirubicin Phase 1b trial, and a preclinical progress update on its MNPR-101 RIT program. February 2023: Camsirubicin Phase 1b Clinical Trial Data Update: In addition to the previously reported improvement in median progression free survival over the prior camsirubicin Phase 2 study, Monopar plans to provide details of the Phase 1b trial’s improved toxicity and safety observed to date compared to doxorubicin. MNPR-101 Radioimmunotherapeutic (RIT) Preclinical Data Update: Monopar plans to report an update on recently generated preclinical data and anticipated next steps with partner NorthStar Medical Radioisotopes. March 2023: Interim Go/no-go Analysis for Validive Phase 2b/3 VOICE Trial: Monopar expects to have the interim analysis completed and to report out the go/no-go decision during March 2023; in the intervening time, patient enrollment and addition of new sites continue in preparation for a potentially positive interim.Price Target Changed • Jan 24Price target increased by 12% to US$19.29Up from US$17.25, the current price target is an average from 5 analysts. New target price is 505% above last closing price of US$3.19. Stock is up 14% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$0.73 last year.お知らせ • Jan 19Monopar Therapeutics Inc. Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2Monopar Therapeutics Inc. announced the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a review of safety data from the patients in the first four dose cohorts. Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. It has been previously investigated in ASTS patients in a Phase 1 and a single-arm Phase 2 clinical trial. In these studies, no camsirubicin-treated patients developed the irreversible cardiotoxicity common to doxorubicin at higher cumulative doses. The most frequent adverse event observed in the Phase 1 study was neutropenia, which was mitigated in the Phase 2 study using prophylactic G-CSF. Based on encouraging clinical results from prior clinical trials, the current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia. Soft tissue sarcomas (STS) are a diverse type of cancer that typically develop in the connective tissue of the body.分析記事 • Nov 16We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Arthur Klausner was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Oct 05Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of ValidiveMonopar Therapeutics (NASDAQ:MNPR) said it completed enrollment in the phase 2b portion of a phase 2b/3 trial of Validive to treat severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer. Oral mucositis — swelling/irritation in the mouth — is a common, debilitating complication of cancer treatments, mainly chemotherapy and radiation. Monopar said in an Oct. 5 release that it enrolled more than 130 patients, activated 68 sites, expanded the trial to include sites in Germany and Poland, and began enrollment for the phase 3 portion of the trial, dubbed VOICE. Interim analysis of data from the phase 2b part, expected to be reported in Q1 2023, will be used to decide whether to continue enrolling in the phase 3 portion of the trial, the company added. MNPR +18.82% to $2.02 premarket Oct. 5Price Target Changed • Aug 04Price target increased to US$32.67Up from US$27.25, the current price target is an average from 4 analysts. New target price is 1,575% above last closing price of US$1.95. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$0.73 last year.分析記事 • Jul 30We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Arthur Klausner was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Mar 28Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Price Target Changed • Feb 03Price target increased to US$32.67Up from US$27.25, the current price target is an average from 4 analysts. New target price is 1,067% above last closing price of US$2.80. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$0.71 next year compared to a net loss per share of US$0.58 last year.Price Target Changed • Nov 16Price target increased to US$33.33Up from US$26.50, the current price target is an average from 4 analysts. New target price is 586% above last closing price of US$4.86. Stock is down 2.0% over the past year. The company is forecast to post a net loss per share of US$0.71 next year compared to a net loss per share of US$0.58 last year.分析記事 • Jul 15We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Breakeven Date Change • May 18Forecast to breakeven in 2025The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.14m in 2025. Average annual earnings growth of 7.1% is required to achieve expected profit on schedule.分析記事 • Mar 26Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Is New 90 Day High Low • Jan 29New 90-day high: US$8.51The company is up 92% from its price of US$4.44 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$3.01 per share.Price Target Changed • Jan 29Price target raised to US$33.33Up from US$26.50, the current price target is an average from 2 analysts. The new target price is 292% above the current share price of US$8.51. As of last close, the stock is down 49% over the past year.Is New 90 Day High Low • Dec 10New 90-day high: US$5.66The company is up 4.0% from its price of US$5.45 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Nov 04New 90-day low: US$4.43The company is down 38% from its price of US$7.20 on 06 August 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 20New 90-day low: US$4.86The company is down 37% from its price of US$7.68 on 22 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 24New 90-day low: US$4.98The company is down 23% from its price of US$6.47 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.株主還元MNPRUS BiotechsUS 市場7D6.5%1.2%1.1%1Y78.1%34.6%28.7%株主還元を見る業界別リターン: MNPR過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を上回りました。リターン対市場: MNPR過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is MNPR's price volatile compared to industry and market?MNPR volatilityMNPR Average Weekly Movement9.2%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: MNPR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MNPRの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201422Chandler Robinsonwww.monopartx.comモノパー・セラピューティクス社は臨床段階にあるバイオ医薬品企業で、米国でがん治療薬の開発に取り組んでいる。MNPR-101は、ウロキナーゼ・プラスミノーゲン活性化因子受容体を発現する進行固形癌の治療薬として、異なる放射性同位元素と結合した独自のヒト化モノクローナル抗体です。MNPR-101-Zrは、ジルコニウム-89と結合したMNPR-101からなる放射性医薬品イメージング剤で、第1相イメージングおよび線量測定の臨床試験中です。MNPR-101-Luは、アクチニウム-225と結合したMNPR-101からなるフェーズ1a段階の放射線治療薬である。同社は、重篤なCOVID-19を標的とした放射線免疫治療薬を開発するNorthStar社、治験用画像診断薬MNPR-101-Zrおよび治験用治療薬MNPR-101-Luを開発するExcel Diagnostics社およびNuclear Oncology Center社、ウィルソン病治療薬候補ALXN1840を開発・商業化するAlexion社とのライセンス契約を締結している。同社は2014年に設立され、イリノイ州ウィルメットに本社を置いている。もっと見るMonopar Therapeutics Inc. 基礎のまとめMonopar Therapeutics の収益と売上を時価総額と比較するとどうか。MNPR 基礎統計学時価総額US$422.83m収益（TTM）-US$14.98m売上高(TTM)n/a0.0xP/Sレシオ-28.2xPER（株価収益率MNPR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MNPR 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$14.98m収益-US$14.98m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.24グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%MNPR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 08:35終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Monopar Therapeutics Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Etzer DaroutBarclaysBrian Kemp DolliverBrookline Capital MarketsSuranjit MukherjeeBTIG14 その他のアナリストを表示
お知らせ • May 21Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMonopar Therapeutics Inc. announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.” The publication reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease, driven by increased fecal copper excretion. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. The open-label, single-arm Phase 2 trial evaluated daily dosing of ALXN1840 in nine patients with Wilson disease across two centers in the United Kingdom and New Zealand. Patients were admitted to a clinical research unit and initiated on a copper-controlled diet, with all copper intake and output collected during a pre-treatment baseline period and after initiation of daily ALXN1840 over multiple weeks. The publication builds on a recently published peer-reviewed Journal of Hepatology Letter to the Editor, which highlighted the importance of comparing outcomes to a pre-treatment baseline to accurately assess the effect of a potential Wilson disease treatment on copper balance. Statistically significant reduction in daily copper balance from baseline, due to increased fecal copper excretion. Cumulative mean decrease from baseline in copper balance of -6.08 mg over 21 days (95% CI: -10.18 mg to -1.98 mg). Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during the 15 mg/day treatment period and -0.29 mg (p=0.023) through the overall study period. Approximately 50% increase in the daily fecal copper output-to-intake ratio compared to baseline (p=0.041). Immediate increases in plasma total copper and directly measured non-ceruloplasmin-bound copper (dNCC), consistent with copper mobilization and formation of stable albumin tripartite complexes (ATCs) consisting of copper, ALXN1840, and albumin. ALXN1840 was generally well tolerated; no serious adverse events were reported. The observed improvements in copper balance and copper mobilization occurred in a Wilson disease patient population with a mean prior current standard of care treatment duration of 16 years, suggesting that despite years of treatment with currently available therapies, patients present with a considerable amount of residual copper in the body that ALXN1840 is able to mobilize and eliminate. This finding is consistent with data from the completed 48-week Phase 3 trial, in which ALXN1840 demonstrated superior copper mobilization compared to standard of care even in patients with a mean prior standard of care treatment duration of 11 years. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.
分析記事 • May 07Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • May 04Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026. Location: at 1000 skokie blvd., wilmette, il 60091, United States
お知らせ • Apr 20Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic SymptomsMonopar Therapeutics Inc. announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department of Neurology, University of Louisville School of Medicine, will present results showing that ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable neurologic benefit observed over multiple years of treatment. In the randomized FoCus trial, analysis of patients with neurologic symptoms at baseline (TMC: n=77; SoC: n=35) demonstrated that treatment with ALXN1840 resulted in both higher rates of improvement and lower rates of worsening, addressing a critical unmet need in the neurologic management of Wilson disease. Clinically meaningful neurologic worsening at Week 48 was observed in 25% of patients treated with standard of care vs 9% of ALXN1840-treated patients (p=0.038). Clinically meaningful neurologic improvement at Week 48 was observed in 45% of ALXN1840-treated patients vs 32% on standard of care. CGI-S improvement from baseline to Week 48 was greater with ALXN1840 vs standard of care (61% vs 17%; p=0.008). CGI-I improvement at Week 48 was greater with ALXN1840 vs standard of care (47% vs 19%; p=0.003). Durable neurologic benefit in the ALXN1840-treated group continued to increase during long-term follow-up on treatment and was sustained over approximately 3 years. Neurologic benefit was consistent across both treatment-naïve and treatment-experienced patients with neurologic symptoms at baseline, supporting ALXN1840’s potential as a novel treatment option for Wilson disease. ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious adverse events (SAEs) limited to 4.9% of patients — including neurologic SAEs in < 1% — and no treatment-related deaths. These findings support the continued advancement of ALXN1840 toward the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026. Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body's ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.
Recent Insider Transactions Derivative • Apr 07Co-Founder exercised options and sold US$108k worth of stockOn the 31st of March, Chandler Robinson exercised options to acquire 2k shares at no cost and sold these for an average price of US$54.79 per share. This trade did not impact their existing holding. For the year to December 2019, Chandler's total compensation was 53% salary and 47% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Chandler's direct individual holding has increased from 73.47k shares to 153.29k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Mar 03Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective March 2, 2026. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. Susan Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.
お知らせ • May 21Monopar Therapeutics Inc Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMonopar Therapeutics Inc. announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.” The publication reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily copper balance in patients with Wilson disease, driven by increased fecal copper excretion. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in organs such as the liver and brain. The open-label, single-arm Phase 2 trial evaluated daily dosing of ALXN1840 in nine patients with Wilson disease across two centers in the United Kingdom and New Zealand. Patients were admitted to a clinical research unit and initiated on a copper-controlled diet, with all copper intake and output collected during a pre-treatment baseline period and after initiation of daily ALXN1840 over multiple weeks. The publication builds on a recently published peer-reviewed Journal of Hepatology Letter to the Editor, which highlighted the importance of comparing outcomes to a pre-treatment baseline to accurately assess the effect of a potential Wilson disease treatment on copper balance. Statistically significant reduction in daily copper balance from baseline, due to increased fecal copper excretion. Cumulative mean decrease from baseline in copper balance of -6.08 mg over 21 days (95% CI: -10.18 mg to -1.98 mg). Mean daily copper balance change from baseline of -0.37 mg (p=0.005) during the 15 mg/day treatment period and -0.29 mg (p=0.023) through the overall study period. Approximately 50% increase in the daily fecal copper output-to-intake ratio compared to baseline (p=0.041). Immediate increases in plasma total copper and directly measured non-ceruloplasmin-bound copper (dNCC), consistent with copper mobilization and formation of stable albumin tripartite complexes (ATCs) consisting of copper, ALXN1840, and albumin. ALXN1840 was generally well tolerated; no serious adverse events were reported. The observed improvements in copper balance and copper mobilization occurred in a Wilson disease patient population with a mean prior current standard of care treatment duration of 16 years, suggesting that despite years of treatment with currently available therapies, patients present with a considerable amount of residual copper in the body that ALXN1840 is able to mobilize and eliminate. This finding is consistent with data from the completed 48-week Phase 3 trial, in which ALXN1840 demonstrated superior copper mobilization compared to standard of care even in patients with a mean prior standard of care treatment duration of 11 years. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.
分析記事 • May 07Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • May 04Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026Monopar Therapeutics Inc., Annual General Meeting, Jun 22, 2026. Location: at 1000 skokie blvd., wilmette, il 60091, United States
お知らせ • Apr 20Monopar Therapeutics Inc. Presents Phase 3 Data Showing Greater Neurologic Benefit With ALXN1840 Versus Standard of Care In Wilson Disease Patients With Neurologic SymptomsMonopar Therapeutics Inc. announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. In a late-breaker oral and poster presentation titled “Greater clinical benefit with tiomolibdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial,” Dr. Peter Hedera, MD, PhD, Department of Neurology, University of Louisville School of Medicine, will present results showing that ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care through Week 48, with durable neurologic benefit observed over multiple years of treatment. In the randomized FoCus trial, analysis of patients with neurologic symptoms at baseline (TMC: n=77; SoC: n=35) demonstrated that treatment with ALXN1840 resulted in both higher rates of improvement and lower rates of worsening, addressing a critical unmet need in the neurologic management of Wilson disease. Clinically meaningful neurologic worsening at Week 48 was observed in 25% of patients treated with standard of care vs 9% of ALXN1840-treated patients (p=0.038). Clinically meaningful neurologic improvement at Week 48 was observed in 45% of ALXN1840-treated patients vs 32% on standard of care. CGI-S improvement from baseline to Week 48 was greater with ALXN1840 vs standard of care (61% vs 17%; p=0.008). CGI-I improvement at Week 48 was greater with ALXN1840 vs standard of care (47% vs 19%; p=0.003). Durable neurologic benefit in the ALXN1840-treated group continued to increase during long-term follow-up on treatment and was sustained over approximately 3 years. Neurologic benefit was consistent across both treatment-naïve and treatment-experienced patients with neurologic symptoms at baseline, supporting ALXN1840’s potential as a novel treatment option for Wilson disease. ALXN1840 has demonstrated a well-characterized and favorable safety profile across Phase 2 and Phase 3 studies (266 patients; median 2.58 years on treatment; max >8 years), with drug-related serious adverse events (SAEs) limited to 4.9% of patients — including neurologic SAEs in < 1% — and no treatment-related deaths. These findings support the continued advancement of ALXN1840 toward the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in mid-2026. Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body's ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated. ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class Albumin Tripartite Complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood–brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 demonstrated rapid and sustained copper mobilization (primary endpoint) that was significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.
Recent Insider Transactions Derivative • Apr 07Co-Founder exercised options and sold US$108k worth of stockOn the 31st of March, Chandler Robinson exercised options to acquire 2k shares at no cost and sold these for an average price of US$54.79 per share. This trade did not impact their existing holding. For the year to December 2019, Chandler's total compensation was 53% salary and 47% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2025, Chandler's direct individual holding has increased from 73.47k shares to 153.29k. Company insiders have collectively sold US$3.1m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Mar 03Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective March 2, 2026. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application to the U.S. Food and Drug Administration in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease. Susan Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.
Recent Insider Transactions Derivative • Jan 07Chief Operating Officer exercised options and sold US$123k worth of stockOn the 31st of December, Andrew Cittadine exercised options to acquire 2k shares at no cost and sold these for an average price of US$65.30 per share. This trade did not impact their existing holding. Since March 2025, Andrew's direct individual holding has increased from 41.99k shares to 50.73k. Company insiders have collectively sold US$2.9m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Dec 30Key Executive recently bought US$105k worth of stockOn the 26th of December, Quan Vu bought around 2k shares on-market at roughly US$69.95 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Quan's only on-market trade for the last 12 months.
Recent Insider Transactions • Dec 21Independent Director recently sold US$344k worth of stockOn the 18th of December, Arthur Klausner sold around 5k shares on-market at roughly US$67.15 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
分析記事 • Nov 22Is There An Opportunity With Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 46% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Monopar Therapeutics fair value estimate is US$168 Current...
お知らせ • Nov 10Monopar Therapeutics Inc. Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025Monopar Therapeutics Inc. announced that it is presenting new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, taking place in Washington, D.C., from November 7-11, 2025. In an oral presentation titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Professor of Hepatology and Consultant Hepatologist at the Institute of Liver Studies at King's College Hospital in London, will be sharing results showing that treatment with ALXN1840 (tiomolybdate choline) led to a rapid and sustained improvement in daily copper balance in patients with Wilson disease, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 in the study (n=8) was significantly lower - indicating improvement - compared with their pre-treatment baseline. Copper balance improved both during the initial 15 mg once-daily dosing period (days 1-28) and over the entire treatment duration (days 1-39), which included patients receiving either 15 mg every other day or 30 mg once daily. Additional new nonclinical and clinical data supporting these findings from the ALXN 1840-WD-204 study will also be presented.
Seeking Alpha • Oct 10Monopar Therapeutics: A Healthy Dose Of Skepticism WarrantedSummary Monopar Therapeutics has surged nearly 2,000% in a year, driven by the acquisition of ALXN-1840 and positive MNPR-101-Zr data. ALXN-1840, acquired from AstraZeneca, targets Wilson disease with an NDA filing anticipated in early 2026, but approval remains uncertain. MNPR's radiopharmaceutical pipeline is in early stages, with limited data and no clear timeline for further results. An analysis around this remarkable biotech comeback story follows in the paragraphs below. Read the full article on Seeking Alpha
Recent Insider Transactions Derivative • Oct 03Chief Operating Officer exercised options and sold US$155k worth of stockOn the 30th of September, Andrew Cittadine exercised options to acquire 2k shares at no cost and sold these for an average price of US$81.67 per share. This trade did not impact their existing holding. Since December 2024, Andrew's direct individual holding has increased from 40.94k shares to 48.29k. Company insiders have collectively sold US$2.3m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Sep 24Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $134.998998 million.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $134.998998 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,034,433 Price\Range: $67.67 Discount Per Security: $4.0602 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 960,542 Price\Range: $67.669 Discount Per Security: $4.0602 Transaction Features: Registered Direct Offering
お知らせ • Sep 15Monopar Therapeutics Inc. to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual MeetingMonopar Therapeutics Inc. announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The analysis pooled efficacy outcomes from three independent clinical trials (n=255), while safety data included a fourth independent clinical trial (n=266). Median treatment duration with ALXN1840 was approximately 2.6 years for both the efficacy and safety analyses. The new data presented at ANA highlight the long-term neurological benefit of ALXN1840, and follow the recent presentation of long-term hepatic and systemic efficacy and safety data at the European Association for the Study of the Liver (EASL) International Liver Congress 2025. Together, these findings underscore the potential of ALXN1840 for both the neurological and hepatic manifestations of Wilson disease. Key findings to be presented at ANA include: Sustained Neurological Improvement: Statistically significant neurologic improvement from baseline on the Unified Wilson Disease Rating Scale ("UWDRS") Part II (patient-reported symptoms) and Part III (clinician-reported symptoms) was sustained over 6 years. Crossover Benefit: Patients who crossed over from standard of care ("SoC") to ALXN1840 showed additional neurological improvement, including a majority of patients who had worsened on SoC demonstrating a reversal on ALXN1840. Psychiatric Outcomes: Statistically significant psychiatric improvement from baseline was sustained over multiple years, as measured by the Brief Psychiatric Rating Scale ("BPRS"). Consistency Across Trials: Neurological benefit was observed consistently across multiple independent studies. Favorable Safety Profile: Across more than 645 patient-years on ALXN1840, less than 1% of patients experienced a drug-related neurological serious adverse event (“SAE”).
New Risk • Sep 03New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$17m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change).
Price Target Changed • Aug 27Price target increased by 8.0% to US$67.17Up from US$62.18, the current price target is an average from 6 analysts. New target price is 93% above last closing price of US$34.81. Stock is up 1,440% over the past year. The company is forecast to post a net loss per share of US$1.77 next year compared to a net loss per share of US$4.11 last year.
Price Target Changed • Jul 07Price target increased by 7.6% to US$63.18Up from US$58.69, the current price target is an average from 6 analysts. New target price is 70% above last closing price of US$37.20. Stock is up 908% over the past year. The company is forecast to post a net loss per share of US$1.98 next year compared to a net loss per share of US$4.11 last year.
お知らせ • Jun 11Monopar Therapeutics Inc. and Excel Diagnostics and Nuclear Oncology Center Announce Expanded Access Program for Mnpr-101-Zr and Mnpr-101-Lu in Advanced CancersMonopar Therapeutics Inc. in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC) announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the U.S. Food and Drug Administration (FDA). The MNPR-101 EAP is now open for enrollment to patients with advanced solid tumors at EDNOC in Houston, Texas. EDNOC is among the first private outpatient facilities in the U.S. to be designated as a Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”). Patients will be treated under the supervision of renowned investigator Ebrahim S. Delpassand, MD, founder and medical director of EDNOC.
お知らせ • May 07Monopar Therapeutics Inc. Presents ALXN1840 Late-Breaker Data At EASL 2025Monopar Therapeutics Inc. is presenting data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025, one of the most prominent global conferences in liver disease. The poster supports the potential use of ALXN1840 as a therapeutic option for Wilson disease, a rare and progressive genetic condition in which the body's pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in tissues and organs such as the liver and brain. Efficacy data were pooled and analyzed from three clinical trials: Phase 2 WTX101-201, Phase 2 ALXN1840-WD-205, and Phase 3 WTX101-301 (n=255). For safety analysis, data from the Phase 2 ALXN18 40-WD-204 trial were also included (n=266). The median treatment duration with ALXN1840 was 961 days (2.63 years) and 943.5 days (2.58 years) for the efficacy and safety datasets, respectively. The data presented highlight the following: Sustained improvements from baseline in the Unified Wilson Disease Rating Scale ("UWDRS") Part II (patient-reported symptoms) and Part III (clinician-assessed symptoms); Increased copper mobilization as evidenced by a sustained increase in dNCC (directly measured non-ceruloplasmin-bound copper); Improvements on the Clinical Global Impression - Improvement ("CGI-I") scale for ALXN1840 compared to standard of care; Improvement in the New Wilson Index (based on bilirubin, AST, INR, leukocytes, and albumin) for patients treated with ALXN1840; Higher patient-reported convenience and effectiveness of ALXN1840 compared To standard of care, including those who transitioned from standard of care to ALXN1840 in the extension portion of the Phase 3 clinical trial; and Fewer than 5% of patients experienced a drug-related serious adverse event ("SAE"), with no cases of a drug-related renal or urinary system SAE.
お知らせ • May 01Monopar Therapeutics Inc., Annual General Meeting, Jun 17, 2025Monopar Therapeutics Inc., Annual General Meeting, Jun 17, 2025. Location: 1000 skokie blvd, wilmette, il 60091, United States
Breakeven Date Change • Apr 02No longer forecast to breakevenThe 4 analysts covering Monopar Therapeutics no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$7.58m in 2027. New consensus forecast suggests the company will make a loss of US$6.91m in 2027.
お知らせ • Apr 01Monopar Therapeutics Inc. Announces Recent Program DevelopmentsMonopar Therapeutics Inc. announced Recent Program Developments. ALXN1840 – Plan to Submit NDA with FDA for Wilson Disease in Early 2026. Wilson disease is a rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised, leading to damage from toxic copper build-up in tissues and organs such as the liver and brain. ALXN1840 is a potent binder and mobilizer of copper, as demonstrated in a Phase 3 clinical trial that met its primary endpoint. In October 2024, Monopar announced the execution of a worldwide exclusive license to ALXN1840 with Alexion, AstraZeneca Rare Disease (“AZ”). As part of this transaction, AZ received a total cash payment of $4.0 million, was issued 9.9% ownership of Monopar’s outstanding common stock, and is entitled to receive regulatory approval and sales milestones along with a tiered royalty based on net sales. MNPR-101 – Currently Enrolling Phase 1 Imaging and Therapeutic Oncology Trials Imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) and therapeutic agent MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) target the urokinase plasminogen activator receptor (“uPAR”), which is expressed in numerous aggressive cancers such as triple-negative breast, colorectal, and pancreatic cancers. · Initiated Phase 1a clinical trial for novel therapeutic radiopharmaceutical MNPR-101-Lu in patients with advanced cancers · Dosed first patient with MNPR-101-Lu in December 2024 · Presented encouraging human clinical imaging and dosimetry data of MNPR-101-Zr at the European Association of Nuclear Medicine (“EANM”) 2024 Annual Congress · uPAR expression, as detected by MNPR-101-Zr, has been seen to date in breast, colorectal, pancreatic, adrenocortical carcinoma, and ovarian cancer patients · Filed a patent application covering new therapeutic radiopharmaceuticals based on a novel family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101.
New Risk • Mar 31New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$6.5m Forecast net loss in 3 years: US$71k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$71k net loss in 3 years).
Price Target Changed • Mar 19Price target increased by 15% to US$53.25Up from US$46.50, the current price target is an average from 4 analysts. New target price is 36% above last closing price of US$39.10. Stock is up 919% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$3.04 last year.
Breakeven Date Change • Mar 06Forecast to breakeven in 2027The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$8.44m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
お知らせ • Mar 05+ 1 more updateMonopar Therapeutics Inc. Announces Executive ChangesOn February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated. As of such date, Mr. Radhakrishan will no longer serve as the Company’s principal financial officer, or principal accounting officer. On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s principal accounting officer and principal financial officer effective March 3, 2025. Mr. Vu brings over 20 years of corporate and financial strategy, investment banking and public company experience. From October 2024 through February 2025, Mr. Vu served as a Venture Partner of ZhongMei Capital. In 2023 he served as Chief Financial Officer and Chief Business Officer of Ocugen Inc. and prior to that, he served as Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. from November 2021 to January 2023. Before joining 180 Life Sciences and since 2019, Mr. Vu has provided services as a consultant/independent contractor through his own consulting firm, Melius BioPharma Consulting. Under Melius, he has served in various capacities for the following companies: 1) LS Associates, a life science services firm and a member company of LifeSci Partners, as an interim C-suite consultant since July 2020; 2) Baleena Bioscience Inc., a biomedical company focused on healthspan, as CEO from April 2021 through October 2021; and 3) Solganick & Co., a technology investment banking firm, as Managing Director and Co-Head of Healthcare IT, from September 2019 through October 2021 and again from August 2024 through February 2025. From September 2016 to August 2019, Mr. Vu served as Vice President and Head of Strategy and Corporate & Business Development at Opiant Pharmaceuticals Inc. Prior to Opiant, he held leadership roles of increasing responsibility at Impax Laboratories Inc., Elevance Health Inc. (formerly Anthem Inc.) and Amgen Inc. Earlier in his career, he worked in the healthcare corporate finance and M&A departments at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. Mr. Vu obtained his MS in Legal Studies from Cornell University Law School and BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).
Seeking Alpha • Mar 04Monopar Therapeutics: Strong Data, But There Are RisksSummary Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results. The market for Wilson Disease treatments is small, with limited pricing power due to existing generic therapies. Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts. Key risks include the need for future funding and competition from Pfizer's gene therapy, VTX-801, which is still years from market. Read the full article on Seeking Alpha
New Risk • Jan 10New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$6.5m Forecast net loss in 3 years: US$13m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (78% average daily change). Shareholders have been substantially diluted in the past year (78% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years).
Breakeven Date Change • Dec 31Forecast to breakeven in 2027The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$3.75m in 2027. Average annual earnings growth of 47% is required to achieve expected profit on schedule.
お知らせ • Dec 21Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $19.000002 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 798,655 Price\Range: $23.79 Transaction Features: Registered Direct Offering
お知らせ • Dec 06Monopar Therapeutics Inc. Doses First Patient with its Novel Therapeutic Radiopharmaceutical MNPR-101-LuMonopar Therapeutics Inc. announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers. The MNPR-101-Lu intravenous infusion was well-tolerated with no serious adverse reactions reported. This patient, dosed under a compassionate use protocol in the US, has metastatic pancreatic cancer, and prior to dosing, the cancer was imaged using MNPR-101-Zr (a zirconium-89 imaging radioisotope conjugated to MNPR-101) with a PET/CT scanner and showed uPAR expression. Monopar is actively enrolling participants in two Phase 1 clinical studies in Australia, evaluating MNPR-101-Zr for imaging and MNPR-101-Lu for treatment of advanced solid tumors.
Price Target Changed • Nov 20Price target increased by 51% to US$27.33Up from US$18.07, the current price target is an average from 3 analysts. New target price is 44% above last closing price of US$19.01. Stock is up 1,191% over the past year. The company is forecast to post a net loss per share of US$1.77 next year compared to a net loss per share of US$3.04 last year.
お知らせ • Oct 31Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million.Monopar Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $19.200025 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,181,540 Price\Range: $16.25 Discount Per Security: $1.1375
New Risk • Oct 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 86% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (77% average daily change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (86% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Market cap is less than US$100m (US$85.6m market cap).
お知らせ • Oct 29Monopar Therapeutics Inc. has filed a Follow-on Equity Offering.Monopar Therapeutics Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
お知らせ • Oct 16Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and LinkersMonopar Therapeutics Inc. announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. Highlights of the patent filing include: Composition of Matter: Claims cover a family of linkers, as well as Monopar's uPAR targeted agents linked with these along with therapeutic radioisotopes; Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar's array of therapeutic radiopharmaceuticals; and that this provisional patent could enable Monopar to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets of interest to Monopar or others in the industry opening the door to potential licensing and development collaborations.
お知らせ • Oct 07Monopar Therapeutics Inc. Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced CancersMonopar Therapeutics Inc. announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to zirconium-177) is now active and recruiting patients with advanced cancers. The Phase 1a trial is an open-label dose-escalation study of MNPR-101-Lu in patients with solid tumors. The first clinical trial site activated for the study is the Melbourne Theranostic Innovation Centre (MTIC) in Australia. To help identify those patients most likely to benefit from MNPR-101-Lu, the trial will only be open to those participating in the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial. MNPR-101 is Monopar's proprietary antibody that targets the urokinase plasminogen activator receptor (uPAR), which is expressed in numerous tumor types including pancreatic, breast, colorectal, ovarian, and bladder. By selectively targeting uPAR, Monopar aims to deliver a radiopharma therapy that kills cancer cells while minimizing damage to healthy tissue. Both clinical (link) and preclinical (link) data to date have demonstrated highly specific and durable tumor uptake of MNPR-101- Zr (MNPR-101 conjUGated to zirconium -89).
お知らせ • Aug 28Monopar Regains Compliance with Nasdaq Minimum Bid Price RuleMonopar Therapeutics Inc. announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company’s common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.
お知らせ • Aug 22Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersMonopar Therapeutics Inc. announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. MNPR-101-Lu combines the therapeutic radioisotope lutetium-177 (Lu-177) with Monopar’s proprietary first-in-class humanized monoclonal antibody MNPR-101, which is highly selective against the urokinase plasminogen activator receptor (uPAR). The MNPR-101-Lu Phase 1 clinical trial will enroll patients with advanced solid cancers and will be a therapeutic follow-on study to the currently ongoing MNPR-101-Zr imaging and dosimetry clinical trial. The results from preclinical studies of MNPR-101-Lu are promising. In a 90-day efficacy study in a human pancreatic cancer xenograft mouse model as an example, MNPR-101-Lu demonstrated durable antitumor effects after a single injection, achieving complete elimination of tumors that lasted the duration of the study. The MNPR-101-Lu imaging data in a human pancreatic cancer xenograft mouse model presented in March provides additional insight into the strong therapeutic effect observed after a single injection of MNPR-101-Lu. The imaging data demonstrates the high specificity and durable uptake of MNPR-101-Lu in the tumor relative to normal tissue.
お知らせ • Aug 14Monopar Therapeutics Inc. Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrMonopar Therapeutics Inc. announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr. MNPR-101-Zr was well-tolerated with no serious adverse reactions reported through the last imaging timepoint and the corresponding initial safety review. Preliminary analysis of MNPR-101-Zr’s pharmacokinetics and biodistribution suggests the low radiation dose to healthy tissue aligns with what was anticipated based on the previously presented MNPR-101-Zr preclinical biodistribution data. Dosimetry analysis showed absorbed organ doses were well below accepted safety limits; for example, the radiation dose to red bone marrow was about 14 mGy, which is around 150 times less than the generally accepted limit of 2-to-3 Gy. No unanticipated or excessive uptake of MNPR-101-Zr was observed in any critical organs through the end of the subject’s imaging period. The patient has metastatic disease from a cancer type not known for high uPAR expression. The study aims to include several patients with cancers known to express high levels of uPAR to gain insight into MNPR-101-Zr’s tumor uptake profile, in addition to patients with cancers of unknown uPAR expression.
分析記事 • Aug 13We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • Aug 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.68m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.2m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.68m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Shareholders have been diluted in the past year (33% increase in shares outstanding).
New Risk • Jul 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.2m free cash flow). Earnings are forecast to decline by an average of 17% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (33% increase in shares outstanding). Market cap is less than US$100m (US$11.3m market cap).
New Risk • Jul 17New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 18% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 18% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (US$12.9m market cap).
お知らせ • Jul 13Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024Monopar Therapeutics Inc., Annual General Meeting, Aug 05, 2024. Location: 1000 skokie blvd., wilmette, il 60091, United States
お知らせ • Jul 09Monopar Therapeutics Inc. Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-ZrMonopar Therapeutics Inc. announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel radiopharmaceutical imaging agent combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the radioisotope zirconium-89. Monopar’s Phase 1 clinical trial, led by internationally recognized nuclear medicine physician Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers. This is the first human study to evaluate a radiolabeled monoclonal antibody targeting uPAR.
お知らせ • May 26Monopar Therapeutics Inc. Announces CFO ChangesMonopar Therapeutics Inc. announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar’s Board of Directors. Monopar has been working over the past 6-plus months on a consulting basis with Karthik Radhakrishnan. Effective July 1, 2024, Mr. Radhakrishnan will be appointed Monopar’s Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer. Mr. Radhakrishnan brings over 20 years of financial strategy, investment and public company experience. Mr. Radhakrishnan has served as President and founder of Titania Partners LLC, a management consulting firm focused on the life science sector during which time he served as Chief Financial Officer of Santalis Pharmaceuticals Inc. and Chief Executive Officer of Asylia Therapeutics Inc. He has also previously served as Chief Financial Officer of Opexa Therapeutics Inc. and before that as Vice President at ING Investment Management in New York. Mr. Radhakrishnan is a Certified Financial Advisor charter holder and holds a B.S. in Chemical Engineering from Indian Institute of Technology, an M.S. in Civil and Environmental Engineering from State University of New York at Buffalo and an M.B.A. from University of Michigan Business School.
Price Target Changed • May 12Price target decreased by 38% to US$2.08Down from US$3.36, the current price target is an average from 2 analysts. New target price is 209% above last closing price of US$0.67. Stock is down 28% over the past year. The company is forecast to post a net loss per share of US$0.36 next year compared to a net loss per share of US$0.61 last year.
お知らせ • Apr 16Monopar Therapeutics Inc. Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsMonopar Therapeutics Inc. announced that it has filed a provisional patent application pertaining to the recent advancements and optimizations Monopar has achieved with its MNPR-101 radiopharmaceutical program. The provisional patent titled “Antibody Radioisotope Constructs” that was filed with the United States Patent and Trademark Office (USPTO) outlines the MNPR-101-Zr construct, including variations on the radioisotopes, linkers, and antibody which could enhance the clinical profile of the construct, including properties such as its stability and biodistribution. It also covers the formulations and uses of MNPR-101-Zr, a zirconium-89 imaging radioisotope labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly-selective against the urokinase plasminogen activator receptor (uPAR). Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR. Monopar recently announced the initiation of its Phase 1 dosimetry clinical trial for MNPR-101-Zr in patients with advanced cancers.
お知らせ • Apr 10Monopar Therapeutics Inc Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsMonopar Therapeutics Inc. announced that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The antibody MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is expressed on numerous tumor types including pancreatic, breast, colorectal, and bladder. The study is now open for enrollment at the Melbourne Theranostic Innovation Centre (MTIC) in Australia, and is being led by Professor Rodney Hicks, an internationally recognized physician and pioneer in the radiopharma space. MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients. The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer. Preclinical data to date have shown highly specific and durable tumor uptake of MNPR-101-Zr in human cancer xenograft models. Moreover, Monopar recently shared positive preclinical efficacy data showing potent and durable anti-tumor activity of MNPR-101 bound to therapeutic radioisotopes. If the tumor uptake, biodistribution, and safety look encouraging in this Phase 1 clinical trial for MNPR-101-Zr, the Company plans to expand the study or initiate a new study to test the potential efficacy of MNPR-101 bound to a therapeutic radioisotope such as Ac-225 in patients with advanced cancers.
Price Target Changed • Apr 01Price target decreased by 52% to US$4.05Down from US$8.50, the current price target is an average from 2 analysts. New target price is 496% above last closing price of US$0.68. Stock is down 53% over the past year. The company is forecast to post a net loss per share of US$0.74 next year compared to a net loss per share of US$0.61 last year.
お知らせ • Mar 05Monopar Therapeutics Inc. Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramMonopar Therapeutics Inc. announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR (urokinase plasminogen activator receptor) targeting agent MNPR-101. The data clearly demonstrate highly preferential uptake in the tumor. This is an extension of the tumor imaging and efficacy data Monopar released on February 22 (link), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models. The new imaging data released provide additional support for the tumor-targeting ability of MNPR-101 and help explain the near complete elimination of tumors observed after a single injection of therapeutic radioisotopes bound to MNPR-101. Two of the most commercially successful radiopharmaceuticals, Pluvicto and Lutathera, use the therapeutic radioisotope Lutetium-177 (Lu-177). Beyond killing cancer cells, this radioisotope has the added advantage that its biodistribution can be visualized via SPECT (single-photon emission computed tomography) imaging. Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model. High specificity and durable uptake of MNPR-101-Lu in the tumor relative to normal tissue is readily apparent, and these results are consistent with the previously released data for Monopar’s diagnostic imaging radiopharmaceutical MNPR-101-Zr. Monopar recently announced it received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients. The data disclosed further support Monopar’s efforts to create a radiodiagnostic and radiotherapeutic pairing to image and treat uPAR-positive cancers.
お知らせ • Feb 29Nasdaq Grants Extension to Monopar Therapeutics to Regain Compliance with the Minimum Bid Price RequirementAs previously reported, on August 28, 2023, Monopar Therapeutics Inc. (the Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq") notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"), and the Company was provided an initial period of 180 calendar days, or until February 26, 2024 (the Compliance Date"), to regain compliance with the Bid Price Requirement. On February 27, 2024, the Company received a letter from Nasdaq notifying that the Company had been granted an additional 180-day extension to August 26, 2024 (Extended Compliance Period") to regain compliance with the Minimum Bid Price Requirement, in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time during the Extended Compliance Period, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days or up to 20 business days in certain circumstances in NASDAQ's discretion, the Staff will provide written confirmation that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company cannot demonstrate compliance during the Extended Compliance Period, the Staff will provide notice that the Company's common stock will be subject to delisting. At that time, the Company may appeal the Staff's determination to a hearings panel. The Company intends to continue to monitor the closing bid price of its common stock and will consider available options to regain compliance with the Minimum Bid Price Requirement, including potentially implementing a reverse stock split (if approved by the Company's shareholders). There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement during the Extended Compliance Period or will otherwise be in compliance with other Nasdaq listing requirements.
分析記事 • Feb 27Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Feb 23Monopar Therapeutics Inc. Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersMonopar Therapeutics Inc. announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program. This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers. MNPR-101 Conjugated to Imaging Radioisotope: Maximizing the dose delivered to the tumor relative to normal tissue is of paramount importance in radiopharmaceutical therapy. Monopar’s in-house radiopharmaceutical development team was able to significantly increase tumor uptake of MNPR-101-Zr while minimizing uptake in healthy tissue, as shown in this preclinical positron emission tomography (PET) sequential imaging time-series. The high specificity and durable tumor uptake are evident in the After Optimization panel below. MNPR-101 Conjugated to Therapeutic Radioisotopes: Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes. Figure 2 below shows preclinical efficacy data in a triple negative breast cancer as well as a pancreatic cancer human tumor xenograft mouse model utilizing two different therapeutic radioisotopes conjugated to MNPR-101; one of these radioisotopes has already been disclosed as being actinium-225 (Ac-225). The results in both show near complete elimination of the tumor after a single injection of the radiopharmaceutical agent. These studies demonstrate the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients.
お知らせ • Feb 20Monopar Receives Clearance to Proceed with First-In-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersMonopar Therapeutics Inc. announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr. The MNPR-101-Zr Phase 1 dosimetry clinical trial will enroll patients with advanced cancers and will utilize positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and safety. MNPR-101-Zr is a zirconium-89 (imaging radioisotope) labeled version of MNPR-101, Monopar’s proprietary first-in-class humanized monoclonal antibody that is highly selective against the urokinase plasminogen activator receptor (uPAR). PET imaging studies in preclinical xenograft models of triple-negative breast, colorectal, and pancreatic cancers displayed high and selective uptake of MNPR-101-Zr in these uPAR-expressing tumors. The imaging results, along with corresponding in vivo efficacy studies with actinium-225 (Ac-225, a powerful alpha-emitting therapeutic radioisotope) bound to MNPR-101 in preclinical xenograft tumor models, support the development MNPR-101 as a targeted radiopharmaceutical for multiple advanced cancer indications. If the tumor uptake, biodistribution, and safety look encouraging in this Phase 1 clinical trial, which is anticipated to enroll around 12 patients and to initiate in the near future, the plan is to evaluate the efficacy in humans of a therapeutically radio-labeled version of MNPR-101 bound to an isotope such as Ac-225.
New Risk • Dec 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$5.42m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Shareholders have been diluted in the past year (16% increase in shares outstanding).
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$7.22m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Shareholders have been diluted in the past year (11% increase in shares outstanding).
お知らせ • Nov 02Monopar Therapeutics Inc. Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingMonopar Therapeutics Inc. will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later on November 1, 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, which is bringing together the world's leading sarcoma specialists. Clinical Trial Results To-Date: The Phase 1b clinical trial has enrolled 14 ASTS patients (9 female and 5 male) to-date ranging in age from 26 to 81 years (median = 52.5 years) across five dose cohorts. The trial is currently ongoing and is in the fifth dose level cohort (650 mg/m2). So far, 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment. All patients in the fourth and fifth cohorts achieved stable disease, including the three most recently treated patients, each of whom also experienced an ~20% tumor size reduction at last study scan. One of these patients had unresectable cancer at study entry, but after the tumor size reduction, the patient became eligible for resection and underwent successful surgical removal of their cancer with clear margins. No dose-limiting toxicity, as defined in the protocol, has been observed to-date. A medically complex patient in the 650 mg/m2 dose cohort has an ongoing left ventricular ejection fraction (LVEF) decrease that is being monitored. This patient has a BMI of 42.5, one kidney, hypertension, a long standing heart murmur, and a maternal history of heart failure. No toxicities have occurred requiring expansion of a dose cohort, and the maximum tolerated dose (MTD) has not been reached.
お知らせ • Sep 01Monopar Therapeutics Receives Letter from Nasdaq Regarding Bid Price RequirementOn August 28, 2023, Monopar Therapeutics Inc. received a letter (the ‘Notice’) from the Listing Qualifications Department (the ‘Staff’) of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Bid Price Requirement’). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq Capital Market under the symbol ‘MNPR.’ In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until February 26, 2024 (the ‘Compliance Date’), to regain compliance with the Bid Price Requirement. If, at any time before the Compliance Date, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide written notification to the Company that it has regained compliance with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10-day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company is not in compliance with the Bid Price Requirement by the Compliance Date, the Company may qualify for a second 180 calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Bid Price Requirement, as of the Compliance Date and would need to provide written notice of its intention to cure the deficiency during the second compliance period. If the Company does not qualify for or fails to regain compliance during the second compliance period, then the Staff will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company may appeal the Staff’s delisting determination to the Nasdaq Hearings Panel. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination, such an appeal would be successful. The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance periods. There can be no assurance that the Company will regain compliance with the minimum bid price requirement during the 180-day compliance period, secure a second period of 180 days to regain compliance or maintain compliance with the other Nasdaq listing requirements.
New Risk • Aug 15New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 8.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 8.1% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.09m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Aug 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 9.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.9% per year for the foreseeable future. Revenue is less than US$1m. Market cap is less than US$10m (US$9.90m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$15m net loss in 3 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).
お知らせ • Aug 09Monopar Therapeutics Inc. Provides Update on Camsirubicin Clinical TrialMonopar Therapeutics Inc. provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Both patients treated to date at the 650 mg/m2 dose level have experienced tumor size reductions – of 18% and 20% respectively – after the first two cycles of camsirubicin treatment. Both patients are set to receive additional cycles of camsirubicin treatment, as well, which may result in further tumor size reduction. The Phase 1b clinical trial data is continuing to support Monopar’s dose-response hypothesis with camsirubicin. The best response seen prior to the current 650 mg/m2 dose level was at the immediately prior dose level (520 mg/m2), which was a 21% reduction in tumor size in a patient after receiving six cycles of camsirubicin treatment. This patient’s cancer was unresectable at study entry, but after the tumor size reduction, became eligible and the patient underwent successful surgical removal of their cancer with clear margins. Furthermore, all three patients at the 520 mg/m2 dose level achieved stable disease and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug. Additionally, no drugrelated cardiotoxicity has been observed in the trial to date as evaluated by the industry standard left ventricular ejection fraction (LVEF), and no toxicities have been experienced by any patient that have required expanding the size of a dose cohort. Further, 71% of camsirubicin patients have experienced no hair loss, and only approximately 14% have experienced >50% hair loss, with the remainder having low grade hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 14% of camsirubicin patients in the Phase 1b trial have experienced mild-to-severe oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin-treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis. ASTS is a deadly cancer with inadequate treatment options. Doxorubicin is currently the first-line standard of care treatment for most types of ASTS, and the average life expectancy from time of diagnosis for these patients is only about 12 to 15 months. Because of the risk of irreversible heart damage, patients discontinue doxorubicin treatment after just 6 to 8 cycles. Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. The value-driving hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes. The purpose of this dose escalation Phase 1b trial is to determine the maximum tolerated dose (MTD) of camsirubicin. Once the MTD is reached, Monopar has a clinical collaboration agreement in place with the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas, or GEIS) to conduct a multi-country randomized Phase 2 clinical trial. The Phase 2 plan is to evaluate camsirubicin head-to-head against doxorubicin in patients with ASTS, with GEIS as the study sponsor with support from Monopar.
New Risk • Jul 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.67m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$9.67m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$13m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (4.8% increase in shares outstanding).
お知らせ • Jun 02Monopar Therapeutics Inc. Announces Encouraging Camsirubicin Phase 1b Trial UpdateMonopar Therapeutics Inc. announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Background on ASTS and Camsirubicin ASTS is a diverse type of cancer that typically develops in the connective tissue of the body and which has metastasized (spread) or is not amenable to surgery. Currently, doxorubicin is the first-line standard of care treatment for most types of ASTS. Doxorubicin is one of the most widely used cancer drugs worldwide with FDA approval in ASTS and 13 additional cancer indications. Unfortunately, although higher doses of doxorubicin are known to be more effective at treating cancer, the risk of irreversible heart damage increases with the cumulative dose and limits the lifetime amount that a patient can receive. The hypothesis for camsirubicin is straightforward: modifying doxorubicin in order to reduce cardiac damage could enable higher and longer dosing, resulting in better efficacy and patient outcomes. Updates from Currently Enrolling Phase 1b Clinical Trial: One patieient at the 520 mg/m2 dose level, unresectable at study entry, was deemed eligible for tumor resection after several cycles of camsirubic in treatment and a corresponding 21% reduction in tumor dimensions. This patient recently underwent surgical resection of the cancer. This is supportive of doseSHY-response hypothesis with camsirubicin. Two patients are currently enrolled in the fifth dose-SHYlevel cohort (650 mg/m2), which is nearly 2.5x the dose evaluated in any prior camsirubicin clinical trial (265mg/m2). No drugSHY-related cardiotoxicity has been observed in this trial to-date as evaluated by the industry standard left ventricular ejection fraction (LVEF). As previously reported, this trial continues to show less frequent and less severe hair loss and oral mucositis with camsirubic in patients with ASTS, with GEIS as the study sponsor with support from Monopar.
Price Target Changed • Mar 29Price target decreased by 49% to US$9.80Down from US$19.29, the current price target is an average from 5 analysts. New target price is 576% above last closing price of US$1.45. Stock is down 44% over the past year. The company is forecast to post a net loss per share of US$0.69 next year compared to a net loss per share of US$0.83 last year.
分析記事 • Mar 02Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
お知らせ • Feb 15Monopar Therapeutics Inc. Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to DoxorubicinMonopar Therapeutics Inc. announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS): Monopar has opened enrollment for the fifth dose level cohort, at an increased dose of 650 mg/m2, which is nearly 2.5x the highest dose evaluated in any prior camsirubicin clinical trial. To date, no drug-related cardiotoxicity has been observed with camsirubicin treatment as evaluated by the industry standard left-ventricular ejection fraction (LVEF). This compares favorably to the well-documented dose-restricting cardiotoxicity experienced with doxorubicin treatment, the current first-line treatment for ASTS. Only 17% of camsirubicin patients in the trial have experienced low grade hair loss; another 8% have experienced >50% hair loss. This compares favorably to the approximately 50% of doxorubicin treated patients in recent ASTS clinical trials reporting some amount of hair loss, with the majority of these patients experiencing >50% hair loss. Only 8% of camsirubicin patients in the trial have experienced low grade mild oral mucositis. This compares favorably to the roughly 35-40% of doxorubicin treated patients in recent ASTS clinical trials that experienced mild-to-severe oral mucositis. In addition to the initial Sarcoma Oncology Research Center clinical trial site in Santa Monica, CA, Monopar recently welcomed a second clinical trial site with Dr. Lee Cranmer and the Sarcoma Clinic at the Fred Hutchinson Cancer Center/University of Washington in Seattle, WA.
お知らせ • Jan 28Monopar Therapeutics Inc. Announces Projected Timeline of Upcoming Quarter 1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RITMonopar Therapeutics Inc. announced it is planning to report over the next two months: the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial, clinical data from its camsirubicin Phase 1b trial, and a preclinical progress update on its MNPR-101 RIT program. February 2023: Camsirubicin Phase 1b Clinical Trial Data Update: In addition to the previously reported improvement in median progression free survival over the prior camsirubicin Phase 2 study, Monopar plans to provide details of the Phase 1b trial’s improved toxicity and safety observed to date compared to doxorubicin. MNPR-101 Radioimmunotherapeutic (RIT) Preclinical Data Update: Monopar plans to report an update on recently generated preclinical data and anticipated next steps with partner NorthStar Medical Radioisotopes. March 2023: Interim Go/no-go Analysis for Validive Phase 2b/3 VOICE Trial: Monopar expects to have the interim analysis completed and to report out the go/no-go decision during March 2023; in the intervening time, patient enrollment and addition of new sites continue in preparation for a potentially positive interim.
Price Target Changed • Jan 24Price target increased by 12% to US$19.29Up from US$17.25, the current price target is an average from 5 analysts. New target price is 505% above last closing price of US$3.19. Stock is up 14% over the past year. The company is forecast to post a net loss per share of US$0.83 next year compared to a net loss per share of US$0.73 last year.
お知らせ • Jan 19Monopar Therapeutics Inc. Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2Monopar Therapeutics Inc. announced the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a review of safety data from the patients in the first four dose cohorts. Camsirubicin is a novel, proprietary analog of the widely used cancer drug doxorubicin. It has been previously investigated in ASTS patients in a Phase 1 and a single-arm Phase 2 clinical trial. In these studies, no camsirubicin-treated patients developed the irreversible cardiotoxicity common to doxorubicin at higher cumulative doses. The most frequent adverse event observed in the Phase 1 study was neutropenia, which was mitigated in the Phase 2 study using prophylactic G-CSF. Based on encouraging clinical results from prior clinical trials, the current Phase 1b trial is designed to test camsirubicin at progressively higher doses than previously administered while using concomitant prophylactic G-CSF to prevent neutropenia. Soft tissue sarcomas (STS) are a diverse type of cancer that typically develop in the connective tissue of the body.
分析記事 • Nov 16We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Arthur Klausner was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Oct 05Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of ValidiveMonopar Therapeutics (NASDAQ:MNPR) said it completed enrollment in the phase 2b portion of a phase 2b/3 trial of Validive to treat severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer. Oral mucositis — swelling/irritation in the mouth — is a common, debilitating complication of cancer treatments, mainly chemotherapy and radiation. Monopar said in an Oct. 5 release that it enrolled more than 130 patients, activated 68 sites, expanded the trial to include sites in Germany and Poland, and began enrollment for the phase 3 portion of the trial, dubbed VOICE. Interim analysis of data from the phase 2b part, expected to be reported in Q1 2023, will be used to decide whether to continue enrolling in the phase 3 portion of the trial, the company added. MNPR +18.82% to $2.02 premarket Oct. 5
Price Target Changed • Aug 04Price target increased to US$32.67Up from US$27.25, the current price target is an average from 4 analysts. New target price is 1,575% above last closing price of US$1.95. Stock is down 63% over the past year. The company is forecast to post a net loss per share of US$0.82 next year compared to a net loss per share of US$0.73 last year.
分析記事 • Jul 30We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Arthur Klausner was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Mar 28Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Price Target Changed • Feb 03Price target increased to US$32.67Up from US$27.25, the current price target is an average from 4 analysts. New target price is 1,067% above last closing price of US$2.80. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$0.71 next year compared to a net loss per share of US$0.58 last year.
Price Target Changed • Nov 16Price target increased to US$33.33Up from US$26.50, the current price target is an average from 4 analysts. New target price is 586% above last closing price of US$4.86. Stock is down 2.0% over the past year. The company is forecast to post a net loss per share of US$0.71 next year compared to a net loss per share of US$0.58 last year.
分析記事 • Jul 15We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Breakeven Date Change • May 18Forecast to breakeven in 2025The 3 analysts covering Monopar Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.14m in 2025. Average annual earnings growth of 7.1% is required to achieve expected profit on schedule.
分析記事 • Mar 26Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Is New 90 Day High Low • Jan 29New 90-day high: US$8.51The company is up 92% from its price of US$4.44 on 30 October 2020. The American market is up 19% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$3.01 per share.
Price Target Changed • Jan 29Price target raised to US$33.33Up from US$26.50, the current price target is an average from 2 analysts. The new target price is 292% above the current share price of US$8.51. As of last close, the stock is down 49% over the past year.
Is New 90 Day High Low • Dec 10New 90-day high: US$5.66The company is up 4.0% from its price of US$5.45 on 10 September 2020. The American market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Nov 04New 90-day low: US$4.43The company is down 38% from its price of US$7.20 on 06 August 2020. The American market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 20New 90-day low: US$4.86The company is down 37% from its price of US$7.68 on 22 July 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 24New 90-day low: US$4.98The company is down 23% from its price of US$6.47 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
